Free Trial

Cross Country Healthcare (CCRN) Financials

Cross Country Healthcare logo
$13.75 -0.19 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$13.75 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Cross Country Healthcare

Annual Income Statements for Cross Country Healthcare

This table shows Cross Country Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
186 73 -15
Consolidated Net Income / (Loss)
186 73 -15
Net Income / (Loss) Continuing Operations
186 73 -15
Total Pre-Tax Income
253 103 -16
Total Operating Income
270 113 -17
Total Gross Profit
2,794 2,005 1,323
Total Revenue
2,803 2,020 1,344
Operating Revenue
2,803 2,020 1,344
Total Cost of Revenue
9.61 15 21
Other Cost of Revenue
9.61 15 21
Total Operating Expenses
2,524 1,892 1,339
Selling, General & Admin Expense
324 300 233
Depreciation Expense
13 18 18
Other Operating Expenses / (Income)
2,180 1,570 1,076
Impairment Charge
5.60 0.72 2.89
Restructuring Charge
1.86 2.61 8.55
Total Other Income / (Expense), net
-17 -9.90 0.47
Interest Expense
18 9.82 2.19
Interest & Investment Income
0.00 0.00 2.05
Other Income / (Expense), net
1.33 -0.09 0.61
Income Tax Expense
67 30 -1.84
Basic Earnings per Share
$5.02 $2.07 ($0.44)
Weighted Average Basic Shares Outstanding
37.01M 35.16M 33.38M
Diluted Earnings per Share
$4.95 $2.05 ($0.44)
Weighted Average Diluted Shares Outstanding
37.54M 35.48M 33.38M
Weighted Average Basic & Diluted Shares Outstanding
36.82M 34.73M 32.81M

Quarterly Income Statements for Cross Country Healthcare

This table shows Cross Country Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
35 36 29 21 13 9.04 2.69 -16 2.56 -3.75
Consolidated Net Income / (Loss)
35 36 29 21 13 9.04 2.69 -16 2.56 -3.75
Net Income / (Loss) Continuing Operations
35 36 29 21 13 9.04 2.69 -16 2.56 -3.75
Total Pre-Tax Income
49 43 40 30 20 13 3.69 -20 3.39 -3.91
Total Operating Income
52 48 44 35 20 13 2.92 -19 2.85 -3.43
Total Gross Profit
635 1,202 618 538 440 410 378 321 314 310
Total Revenue
636 625 623 541 442 414 379 340 315 310
Operating Revenue
636 625 623 541 442 414 379 340 315 310
Total Cost of Revenue
1.10 -577 4.91 3.13 2.36 4.17 1.29 19 1.51 -0.23
Other Cost of Revenue
1.10 - 4.91 3.13 2.36 4.17 1.29 19 1.51 -0.23
Total Operating Expenses
583 1,154 574 502 420 396 375 340 311 314
Selling, General & Admin Expense
81 81 84 79 70 68 63 60 54 56
Depreciation Expense
3.21 3.16 4.90 4.43 4.54 4.47 4.64 4.72 4.50 4.34
Other Operating Expenses / (Income)
493 1,070 484 418 345 324 306 273 251 247
Impairment Charge
3.86 - 0.00 0.53 0.19 - 0.60 0.11 0.00 2.17
Restructuring Charge
2.49 0.00 0.43 0.91 0.35 0.92 0.94 2.12 1.00 4.50
Total Other Income / (Expense), net
-3.47 -5.12 -3.68 -4.88 -0.80 -0.54 0.77 -0.36 0.54 -0.48
Interest Expense
3.50 5.33 3.69 4.87 0.67 0.59 0.46 0.57 0.55 0.61
Other Income / (Expense), net
0.03 0.21 0.01 -0.01 -0.14 0.05 1.23 0.21 -0.02 -0.82
Income Tax Expense
14 6.81 11 8.96 6.69 3.93 1.00 -3.51 0.83 -0.16
Basic Earnings per Share
$0.94 $1.00 $0.82 $0.60 $0.37 $0.28 $0.08 ($0.47) $0.08 ($0.13)
Weighted Average Basic Shares Outstanding
37.10M 37.01M 35.86M 35.35M 34.95M 35.16M 34.22M 33.96M 33.02M 33.38M
Diluted Earnings per Share
$0.93 $0.99 $0.81 $0.60 $0.36 $0.28 $0.08 ($0.47) $0.08 ($0.13)
Weighted Average Diluted Shares Outstanding
37.49M 37.54M 36.56M 35.52M 35.15M 35.48M 34.60M 33.96M 33.06M 33.38M
Weighted Average Basic & Diluted Shares Outstanding
37.30M 36.82M 35.93M 35.80M 35.15M 34.73M 34.77M 33.81M 32.92M 32.81M

Annual Cash Flow Statements for Cross Country Healthcare

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
2.57 13 65
Net Cash From Operating Activities
134 248 120
Net Cash From Continuing Operating Activities
134 248 120
Net Income / (Loss) Continuing Operations
186 73 -15
Consolidated Net Income / (Loss)
186 73 -15
Depreciation Expense
13 18 18
Non-Cash Adjustments To Reconcile Net Income
29 24 28
Changes in Operating Assets and Liabilities, net
-94 133 88
Net Cash From Investing Activities
-44 -14 -8.71
Net Cash From Continuing Investing Activities
-44 -14 -8.71
Purchase of Property, Plant & Equipment
-8.79 -14 -8.71
Acquisitions
-35 0.00 0.00
Other Investing Activities, net
0.09 0.20 0.00
Net Cash From Financing Activities
-88 -221 -47
Net Cash From Continuing Financing Activities
-88 -221 -47
Repayment of Debt
-1,740 -872 -18
Repurchase of Common Equity
-35 -58 -37
Issuance of Debt
1,700 721 18
Other Financing Activities, net
-13 -12 -9.54
Other Net Changes in Cash
-0.01 0.01 -0.01
Cash Interest Paid
13 7.53 1.37
Cash Income Taxes Paid
83 22 2.43

Quarterly Cash Flow Statements for Cross Country Healthcare

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
30 -27 -3.31 0.38 14 2.79 -12 64 -5.58 18
Net Cash From Operating Activities
141 4.32 47 119 70 12 6.01 82 7.47 24
Net Cash From Continuing Operating Activities
141 4.32 47 119 70 12 6.01 82 7.47 24
Net Income / (Loss) Continuing Operations
35 36 29 21 13 9.04 2.69 -16 2.56 -3.75
Consolidated Net Income / (Loss)
35 36 29 21 13 9.04 2.69 -16 2.56 -3.75
Depreciation Expense
3.21 3.16 4.90 4.43 4.54 4.47 4.64 4.72 4.50 4.34
Non-Cash Adjustments To Reconcile Net Income
8.95 4.90 7.43 9.81 5.98 1.15 3.42 22 0.53 2.34
Changes in Operating Assets and Liabilities, net
94 -40 5.10 84 47 -2.58 -4.74 72 -0.11 21
Net Cash From Investing Activities
-2.92 -37 -3.50 -4.00 -3.41 -2.88 -2.21 -2.85 -1.12 -2.53
Net Cash From Continuing Investing Activities
-2.92 -37 -3.50 -4.00 -3.41 -2.88 -2.21 -2.85 -1.12 -2.53
Purchase of Property, Plant & Equipment
-2.92 -2.02 -3.68 -4.00 -3.43 -2.88 -2.21 -2.85 -1.12 -2.53
Net Cash From Financing Activities
-108 6.08 -47 -115 -53 -6.42 -16 -15 -12 -4.08
Net Cash From Continuing Financing Activities
-108 6.08 -47 -115 -53 -6.42 -16 -15 -12 -4.08
Repayment of Debt
-452 -407 -358 -316 -143 -56 -14 -3.15 -0.35 -0.35
Repurchase of Common Equity
-24 -11 -32 -4.72 -15 -6.40 -6.37 -15 -12 -4.08
Issuance of Debt
376 424 347 206 112 56 14 3.15 0.35 0.35
Other Net Changes in Cash
- - -0.00 - - - - - - -0.01

Annual Balance Sheets for Cross Country Healthcare

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
950 681 589
Total Current Assets
677 417 335
Cash & Equivalents
3.60 17 82
Accounts Receivable
642 372 223
Prepaid Expenses
11 7.68 7.85
Current Deferred & Refundable Income Taxes
13 8.62 10
Other Current Assets
8.48 11 12
Plant, Property, & Equipment, net
20 27 29
Total Noncurrent Assets
253 237 225
Noncurrent Note & Lease Receivables
23 26 21
Goodwill
163 135 135
Intangible Assets
45 54 42
Noncurrent Deferred & Refundable Income Taxes
7.12 5.98 8.10
Other Noncurrent Operating Assets
14 15 19
Total Liabilities & Shareholders' Equity
950 681 589
Total Liabilities
498 213 170
Total Current Liabilities
279 156 120
Short-Term Debt
7.50 6.79 4.41
Accounts Payable
193 93 65
Current Employee Benefit Liabilities
73 52 48
Other Current Liabilities
6.03 4.16 3.40
Total Noncurrent Liabilities
70 57 50
Noncurrent Deferred & Payable Income Tax Liabilities
7.65 11 10
Other Noncurrent Operating Liabilities
63 47 40
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
451 468 419
Total Preferred & Common Equity
451 468 419
Total Common Equity
451 468 419
Common Stock
293 236 202
Retained Earnings
160 233 218
Accumulated Other Comprehensive Income / (Loss)
-1.39 -1.39 -1.44

Quarterly Balance Sheets for Cross Country Healthcare

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
883 921 771 708 648 603 597
Total Current Assets
660 649 506 445 387 338 337
Cash & Equivalents
30 0.29 0.67 14 5.24 70 64
Accounts Receivable
611 627 485 410 357 242 245
Prepaid Expenses
3.95 11 6.75 4.78 7.62 6.25 4.55
Current Deferred & Refundable Income Taxes
- 1.78 4.13 5.24 6.33 8.97 10
Other Current Assets
15 8.53 9.20 11 11 11 13
Plant, Property, & Equipment, net
19 23 25 26 28 29 29
Total Noncurrent Assets
204 249 241 236 233 236 232
Noncurrent Note & Lease Receivables
21 23 22 22 23 23 22
Goodwill
113 142 137 135 135 135 135
Intangible Assets
47 63 60 57 52 49 46
Noncurrent Deferred & Refundable Income Taxes
8.79 7.71 7.62 6.53 6.81 10 9.04
Other Noncurrent Operating Assets
14 14 14 15 16 18 19
Total Liabilities & Shareholders' Equity
883 921 771 708 648 603 597
Total Liabilities
460 469 301 238 180 164 173
Total Current Liabilities
277 265 216 184 128 110 121
Short-Term Debt
7.50 13 16 6.91 4.10 4.10 4.10
Accounts Payable
192 177 140 115 69 56 58
Current Employee Benefit Liabilities
71 70 56 57 52 47 54
Other Current Liabilities
6.29 5.84 4.65 4.45 3.82 3.72 3.86
Total Noncurrent Liabilities
183 204 85 55 52 54 52
Capital Lease Obligations
- - - - - - 2.35
Noncurrent Deferred & Payable Income Tax Liabilities
0.24 8.43 9.19 9.91 11 12 11
Other Noncurrent Operating Liabilities
53 57 45 45 40 42 39
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
423 452 470 470 468 439 425
Total Preferred & Common Equity
423 452 470 470 468 439 425
Total Common Equity
423 452 470 470 468 439 425
Common Stock
297 258 255 242 229 215 204
Retained Earnings
127 195 217 229 241 225 222
Accumulated Other Comprehensive Income / (Loss)
-1.37 -1.38 -1.38 -1.39 -1.39 -1.39 -1.40

Annual Metrics and Ratios for Cross Country Healthcare

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
67.20% -27.95% -33.46%
EBITDA Growth
89.28% -53.85% -98.52%
EBIT Growth
93.62% -58.47% -114.44%
NOPAT Growth
43.66% -59.88% -114.84%
Net Income Growth
40.89% -60.95% -120.04%
EPS Growth
40.23% -58.59% -121.46%
Operating Cash Flow Growth
256.57% 85.38% -51.66%
Free Cash Flow Firm Growth
157.33% 187.42% -54.13%
Invested Capital Growth
24.68% -24.29% -25.28%
Revenue Q/Q Growth
-0.56% -9.59% -7.19%
EBITDA Q/Q Growth
-8.76% -21.98% -90.24%
EBIT Q/Q Growth
-9.26% -25.33% -1,149.71%
NOPAT Q/Q Growth
-16.93% -29.75% -40,650.06%
Net Income Q/Q Growth
-18.16% -29.06% -724.70%
EPS Q/Q Growth
-17.91% -27.56% -1,366.67%
Operating Cash Flow Q/Q Growth
137.82% 3.22% 11.26%
Free Cash Flow Firm Q/Q Growth
127.28% 25.29% 9.06%
Invested Capital Q/Q Growth
14.06% -1.06% -6.91%
Profitability Metrics
- - -
Gross Margin
99.66% 99.28% 98.41%
EBITDA Margin
10.12% 6.48% 0.14%
Operating Margin
9.63% 5.58% -1.25%
EBIT Margin
9.67% 5.58% -1.21%
Profit (Net Income) Margin
6.63% 3.60% -1.08%
Tax Burden Percent
73.48% 70.59% 88.77%
Interest Burden Percent
93.32% 91.36% 100.85%
Effective Tax Rate
26.52% 29.41% 0.00%
Return on Invested Capital (ROIC)
36.43% 14.99% -2.95%
ROIC Less NNEP Spread (ROIC-NNEP)
29.17% 5.25% 3.33%
Return on Net Nonoperating Assets (RNNOA)
13.23% 0.81% -0.33%
Return on Equity (ROE)
49.66% 15.80% -3.28%
Cash Return on Invested Capital (CROIC)
14.47% 42.64% 25.98%
Operating Return on Assets (OROA)
32.24% 13.81% -2.56%
Return on Assets (ROA)
22.11% 8.91% -2.29%
Return on Common Equity (ROCE)
49.66% 15.80% -3.28%
Return on Equity Simple (ROE_SIMPLE)
41.19% 15.53% -3.47%
Net Operating Profit after Tax (NOPAT)
198 80 -12
NOPAT Margin
7.07% 3.94% -0.88%
Net Nonoperating Expense Percent (NNEP)
7.26% 9.74% -6.29%
Return On Investment Capital (ROIC_SIMPLE)
43.21% 16.77% -2.79%
Cost of Revenue to Revenue
0.34% 0.72% 1.59%
SG&A Expenses to Revenue
11.56% 14.87% 17.36%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
90.03% 93.70% 99.66%
Earnings before Interest and Taxes (EBIT)
271 113 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
284 131 1.94
Valuation Ratios
- - -
Price to Book Value (P/BV)
2.19 1.70 1.43
Price to Tangible Book Value (P/TBV)
4.07 2.87 2.47
Price to Revenue (P/Rev)
0.35 0.39 0.44
Price to Earnings (P/E)
5.33 10.96 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
18.77% 9.13% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.65 1.72 1.52
Enterprise Value to Revenue (EV/Rev)
0.35 0.39 0.39
Enterprise Value to EBITDA (EV/EBITDA)
3.51 6.00 268.32
Enterprise Value to EBIT (EV/EBIT)
3.67 6.97 0.00
Enterprise Value to NOPAT (EV/NOPAT)
5.02 9.87 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
7.42 3.16 4.33
Enterprise Value to Free Cash Flow (EV/FCFF)
12.63 3.47 5.01
Leverage & Solvency
- - -
Debt to Equity
0.02 0.01 0.01
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
0.45 0.15 -0.10
Leverage Ratio
2.25 1.77 1.43
Compound Leverage Factor
2.10 1.62 1.44
Debt to Total Capital
1.63% 1.43% 1.04%
Short-Term Debt to Total Capital
1.63% 1.43% 1.04%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
98.37% 98.57% 98.96%
Debt to EBITDA
0.03 0.05 2.27
Net Debt to EBITDA
0.01 -0.08 -39.81
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.04 0.09 -0.37
Net Debt to NOPAT
0.02 -0.13 6.54
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
5.83 6.69 5.25
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
2.43 2.67 2.78
Quick Ratio
2.31 2.50 2.53
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
79 226 104
Operating Cash Flow to CapEx
1,525.72% 1,778.29% 1,378.43%
Free Cash Flow to Firm to Interest Expense
4.35 23.05 47.44
Operating Cash Flow to Interest Expense
7.40 25.31 54.90
Operating Cash Flow Less CapEx to Interest Expense
6.91 23.89 50.92
Efficiency Ratios
- - -
Asset Turnover
3.33 2.48 2.12
Accounts Receivable Turnover
4.94 3.98 4.51
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
157.96 85.94 47.84
Accounts Payable Turnover
0.06 0.10 0.27
Days Sales Outstanding (DSO)
73.92 91.62 80.87
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
5,749.99 3,582.05 1,343.44
Cash Conversion Cycle (CCC)
-5,676.07 -3,490.43 -1,262.57
Capital & Investment Metrics
- - -
Invested Capital
604 457 342
Invested Capital Turnover
5.15 3.81 3.36
Increase / (Decrease) in Invested Capital
120 -147 -116
Enterprise Value (EV)
995 786 521
Market Capitalization
991 796 598
Book Value per Share
$12.11 $13.30 $12.73
Tangible Book Value per Share
$6.53 $7.90 $7.34
Total Capital
459 474 423
Total Debt
7.50 6.79 4.41
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
3.90 -10 -77
Capital Expenditures (CapEx)
8.79 14 8.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)
402 250 137
Debt-free Net Working Capital (DFNWC)
406 268 219
Net Working Capital (NWC)
398 261 215
Net Nonoperating Expense (NNE)
12 6.93 2.75
Net Nonoperating Obligations (NNO)
153 -10 -77
Total Depreciation and Amortization (D&A)
13 18 18
Debt-free, Cash-free Net Working Capital to Revenue
14.35% 12.40% 10.22%
Debt-free Net Working Capital to Revenue
14.47% 13.25% 16.30%
Net Working Capital to Revenue
14.21% 12.91% 15.97%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$5.09 $2.07 ($0.44)
Adjusted Weighted Average Basic Shares Outstanding
37.01M 35.16M 33.38M
Adjusted Diluted Earnings per Share
$5.02 $2.05 ($0.44)
Adjusted Weighted Average Diluted Shares Outstanding
37.54M 35.48M 33.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
36.82M 34.73M 32.81M
Normalized Net Operating Profit after Tax (NOPAT)
204 82 -3.80
Normalized NOPAT Margin
7.27% 4.06% -0.28%
Pre Tax Income Margin
9.03% 5.09% -1.22%
Debt Service Ratios
- - -
EBIT to Interest Expense
14.97 11.47 -7.43
NOPAT to Interest Expense
10.95 8.10 -5.40
EBIT Less CapEx to Interest Expense
14.48 10.05 -11.41
NOPAT Less CapEx to Interest Expense
10.46 6.68 -9.38
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
18.97% 79.38% -256.32%

Quarterly Metrics and Ratios for Cross Country Healthcare

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
69.67% -2.45% -21.05% -28.25% -30.47% -33.75% -39.11% -37.16% -28.75% -25.14%
EBITDA Growth
87.84% -34.54% -47.82% -52.51% -55.42% -65.22% -81.95% -136.04% -70.33% -99.49%
EBIT Growth
94.62% -36.36% -51.67% -55.98% -61.37% -72.18% -90.52% -153.99% -85.96% -131.53%
NOPAT Growth
48.19% -49.47% -50.17% -55.93% -64.21% -76.97% -93.37% -154.25% -83.88% -125.69%
Net Income Growth
48.48% -53.19% -52.51% -59.65% -63.18% -75.11% -90.85% -175.19% -80.06% -141.52%
EPS Growth
50.00% -52.17% -50.31% -57.14% -61.29% -71.72% -90.12% -178.33% -77.78% -146.43%
Operating Cash Flow Growth
5,067.40% 105.89% 261.39% 557.34% -50.00% 179.49% -87.17% -30.90% -89.38% 100.71%
Free Cash Flow Firm Growth
-68.71% 59.51% 104.91% 147.22% 148.38% 297.72% 967.79% -1.71% 20.55% -27.48%
Invested Capital Growth
62.69% 24.68% 3.30% -17.15% -12.72% -24.29% -22.49% -27.67% -20.58% -25.28%
Revenue Q/Q Growth
-15.59% -1.75% -0.88% -13.17% -18.20% -6.39% -8.42% -10.39% -7.26% -1.64%
EBITDA Q/Q Growth
-33.56% -6.88% -11.18% -18.69% -37.63% -27.35% -51.22% -262.35% 151.35% -98.74%
EBIT Q/Q Growth
-34.68% -7.20% -15.23% -19.70% -42.68% -33.16% -69.38% -557.58% 114.91% -250.04%
NOPAT Q/Q Growth
-33.72% 8.98% -25.39% -22.87% -46.18% -29.87% -77.21% -730.72% 116.00% -211.73%
Net Income Q/Q Growth
-34.22% 4.37% -24.12% -27.49% -39.98% -29.46% -70.21% -696.21% 115.92% -246.89%
EPS Q/Q Growth
-33.57% 6.45% -23.58% -25.93% -40.00% -22.22% -71.43% -687.50% 117.02% -262.50%
Operating Cash Flow Q/Q Growth
675.19% -96.93% 984.84% 154.45% -41.04% -82.83% -50.22% 1,270.84% -90.93% 224.42%
Free Cash Flow Firm Q/Q Growth
40.20% 52.67% 115.68% 921.65% -38.72% 93.41% -11.82% -5.95% -24.85% 16.35%
Invested Capital Q/Q Growth
-15.04% 14.06% -1.19% -14.29% -10.50% -1.06% 0.85% -20.02% -1.72% -6.91%
Profitability Metrics
- - - - - - - - - -
Gross Margin
99.83% 192.32% 99.21% 99.42% 99.47% 98.99% 99.66% 94.45% 99.52% 100.07%
EBITDA Margin
8.71% 8.26% 7.82% 7.33% 5.59% 4.33% 2.32% -4.20% 2.33% 0.03%
Operating Margin
8.20% 7.72% 7.03% 6.51% 4.59% 3.24% 0.77% -5.65% 0.91% -1.11%
EBIT Margin
8.21% 7.75% 7.04% 6.51% 4.56% 3.26% 1.09% -5.59% 0.90% -1.37%
Profit (Net Income) Margin
5.47% 5.81% 4.73% 3.95% 2.90% 2.18% 0.71% -4.72% 0.81% -1.21%
Tax Burden Percent
71.44% 84.21% 73.37% 70.43% 65.70% 69.69% 72.97% 82.05% 75.39% 95.89%
Interest Burden Percent
93.30% 89.02% 91.58% 86.15% 96.71% 96.23% 88.87% 102.99% 119.67% 92.12%
Effective Tax Rate
28.56% 15.79% 26.63% 29.57% 34.30% 30.31% 27.03% 0.00% 24.61% 0.00%
Return on Invested Capital (ROIC)
38.63% 33.47% 22.98% 19.53% 13.58% 8.60% 1.87% -14.01% 2.38% -2.61%
ROIC Less NNEP Spread (ROIC-NNEP)
36.33% 30.94% 21.55% 16.87% 12.52% 8.15% 2.62% 12.89% 1.14% 0.48%
Return on Net Nonoperating Assets (RNNOA)
12.25% 14.03% 10.08% 4.95% 1.40% 1.26% 0.43% -0.27% -0.08% -0.05%
Return on Equity (ROE)
50.88% 47.50% 33.06% 24.48% 14.98% 9.86% 2.29% -14.28% 2.30% -2.66%
Cash Return on Invested Capital (CROIC)
8.10% 14.47% 25.18% 42.84% 36.42% 42.64% 34.62% 34.12% 22.95% 25.98%
Operating Return on Assets (OROA)
32.98% 25.83% 20.23% 18.47% 12.81% 8.06% 2.48% -12.82% 1.99% -2.90%
Return on Assets (ROA)
21.98% 19.36% 13.59% 11.21% 8.14% 5.41% 1.61% -10.83% 1.80% -2.56%
Return on Common Equity (ROCE)
50.88% 47.50% 33.06% 24.48% 14.98% 9.86% 2.29% -14.28% 2.30% -2.66%
Return on Equity Simple (ROE_SIMPLE)
53.76% 0.00% 34.50% 26.44% 21.80% 0.00% 9.80% 1.93% -0.42% 0.00%
Net Operating Profit after Tax (NOPAT)
37 41 32 25 13 9.36 2.13 -13 2.15 -2.40
NOPAT Margin
5.86% 6.50% 5.16% 4.58% 3.02% 2.26% 0.56% -3.96% 0.68% -0.78%
Net Nonoperating Expense Percent (NNEP)
2.30% 2.54% 1.43% 2.66% 1.06% 0.45% -0.75% -26.90% 1.24% -3.08%
Return On Investment Capital (ROIC_SIMPLE)
- 8.85% - - - 1.97% - - - -0.57%
Cost of Revenue to Revenue
0.17% -92.32% 0.79% 0.58% 0.53% 1.01% 0.34% 5.55% 0.48% -0.07%
SG&A Expenses to Revenue
12.69% 12.90% 13.53% 14.60% 15.74% 16.30% 16.68% 17.73% 17.23% 17.93%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
91.62% 184.61% 92.18% 92.91% 94.88% 95.75% 98.89% 100.10% 98.61% 101.18%
Earnings before Interest and Taxes (EBIT)
52 48 44 35 20 13 4.15 -19 2.83 -4.25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
55 52 49 40 25 18 8.79 -14 7.33 0.09
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.57 2.19 1.82 2.15 1.89 1.70 1.41 1.10 1.07 1.43
Price to Tangible Book Value (P/TBV)
4.13 4.07 3.32 3.69 3.20 2.87 2.34 1.89 1.87 2.47
Price to Revenue (P/Rev)
0.38 0.35 0.31 0.42 0.40 0.39 0.37 0.31 0.31 0.44
Price to Earnings (P/E)
4.77 5.33 5.27 8.11 8.67 10.96 14.34 56.67 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
20.95% 18.77% 18.97% 12.33% 11.54% 9.13% 6.97% 1.76% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.25 1.65 1.61 2.04 1.90 1.72 1.41 1.11 1.08 1.52
Enterprise Value to Revenue (EV/Rev)
0.42 0.35 0.37 0.43 0.39 0.39 0.37 0.26 0.27 0.39
Enterprise Value to EBITDA (EV/EBITDA)
3.83 3.51 4.01 5.31 5.24 6.00 7.21 11.16 19.96 268.32
Enterprise Value to EBIT (EV/EBIT)
3.99 3.67 4.27 5.77 5.84 6.97 8.99 22.02 256.17 0.00
Enterprise Value to NOPAT (EV/NOPAT)
4.99 5.02 5.77 7.69 7.77 9.87 13.24 46.59 13,629.97 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
21.14 7.42 4.63 3.39 3.66 3.16 3.16 2.43 3.68 4.33
Enterprise Value to Free Cash Flow (EV/FCFF)
34.39 12.63 6.51 4.32 4.87 3.47 3.55 2.74 4.17 5.01
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.32 0.02 0.33 0.10 0.01 0.01 0.01 0.01 0.02 0.01
Long-Term Debt to Equity
0.31 0.00 0.31 0.07 0.00 0.00 0.00 0.00 0.01 0.00
Financial Leverage
0.34 0.45 0.47 0.29 0.11 0.15 0.16 -0.02 -0.07 -0.10
Leverage Ratio
2.19 2.25 2.27 1.94 1.78 1.77 1.71 1.51 1.46 1.43
Compound Leverage Factor
2.05 2.00 2.08 1.67 1.72 1.71 1.52 1.56 1.75 1.32
Debt to Total Capital
24.51% 1.63% 25.04% 9.05% 1.45% 1.43% 0.87% 0.93% 1.50% 1.04%
Short-Term Debt to Total Capital
1.34% 1.63% 2.07% 3.06% 1.45% 1.43% 0.87% 0.93% 0.95% 1.04%
Long-Term Debt to Total Capital
23.17% 0.00% 22.96% 5.99% 0.00% 0.00% 0.00% 0.00% 0.54% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
75.49% 98.37% 74.96% 90.95% 98.55% 98.57% 99.13% 99.07% 98.50% 98.96%
Debt to EBITDA
0.44 0.03 0.62 0.24 0.04 0.05 0.05 0.11 0.32 2.27
Net Debt to EBITDA
0.34 0.01 0.62 0.23 -0.04 -0.08 -0.01 -1.76 -2.90 -39.81
Long-Term Debt to EBITDA
0.42 0.00 0.57 0.16 0.00 0.00 0.00 0.00 0.12 0.00
Debt to NOPAT
0.57 0.04 0.90 0.34 0.06 0.09 0.08 0.46 221.48 -0.37
Net Debt to NOPAT
0.45 0.02 0.89 0.34 -0.07 -0.13 -0.02 -7.34 -1,977.54 6.54
Long-Term Debt to NOPAT
0.54 0.00 0.82 0.23 0.00 0.00 0.00 0.00 80.65 0.00
Altman Z-Score
5.53 5.05 4.87 6.16 6.38 6.21 5.95 5.25 4.97 5.32
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.38 2.43 2.45 2.34 2.43 2.67 3.02 3.07 2.79 2.78
Quick Ratio
2.32 2.31 2.37 2.25 2.31 2.50 2.82 2.83 2.56 2.53
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-167 -79 13 132 81 156 138 129 97 113
Operating Cash Flow to CapEx
4,824.25% 213.54% 1,274.20% 2,984.18% 2,052.88% 419.97% 271.99% 2,892.28% 664.59% 957.49%
Free Cash Flow to Firm to Interest Expense
-47.69 -14.81 3.49 27.04 120.65 266.40 297.98 227.94 176.91 186.20
Operating Cash Flow to Interest Expense
40.20 0.81 12.70 24.48 105.10 20.60 13.01 145.07 13.58 39.86
Operating Cash Flow Less CapEx to Interest Expense
39.37 0.43 11.70 23.66 99.98 15.70 8.23 140.06 11.54 35.70
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
4.02 3.33 2.87 2.84 2.81 2.48 2.26 2.29 2.22 2.12
Accounts Receivable Turnover
6.18 4.94 4.05 4.09 4.37 3.98 3.61 4.33 4.42 4.51
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
168.64 157.96 132.73 112.69 99.69 85.94 69.27 58.48 52.43 47.84
Accounts Payable Turnover
14.23 0.06 12.79 9.72 10.45 0.10 12.74 16.20 18.25 0.27
Days Sales Outstanding (DSO)
59.04 73.92 90.16 89.22 83.43 91.62 101.16 84.25 82.59 80.87
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
25.65 5,749.99 28.54 37.53 34.94 3,582.05 28.65 22.53 20.00 1,343.44
Cash Conversion Cycle (CCC)
33.39 -5,676.07 61.62 51.68 48.49 -3,490.43 72.51 61.72 62.59 -1,262.57
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
530 604 603 516 462 457 467 374 367 342
Invested Capital Turnover
6.59 5.15 4.45 4.26 4.50 3.81 3.32 3.54 3.49 3.36
Increase / (Decrease) in Invested Capital
204 120 19 -107 -67 -147 -136 -143 -95 -116
Enterprise Value (EV)
1,192 995 972 1,055 880 786 657 416 397 521
Market Capitalization
1,085 991 822 1,009 888 796 658 481 454 598
Book Value per Share
$11.06 $12.11 $12.27 $13.09 $13.12 $13.30 $13.68 $12.63 $12.56 $12.73
Tangible Book Value per Share
$6.87 $6.53 $6.72 $7.60 $7.74 $7.90 $8.21 $7.32 $7.18 $7.34
Total Capital
560 459 603 517 477 474 472 443 431 423
Total Debt
137 7.50 151 47 6.91 6.79 4.10 4.10 6.45 4.41
Total Long-Term Debt
130 0.00 138 31 0.00 0.00 0.00 0.00 2.35 0.00
Net Debt
107 3.90 151 46 -7.39 -10 -1.14 -66 -58 -77
Capital Expenditures (CapEx)
2.92 2.02 3.68 4.00 3.43 2.88 2.21 2.85 1.12 2.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)
360 402 396 305 254 250 258 162 156 137
Debt-free Net Working Capital (DFNWC)
391 406 396 305 269 268 263 232 220 219
Net Working Capital (NWC)
383 398 384 290 262 261 259 228 216 215
Net Nonoperating Expense (NNE)
2.48 4.31 2.70 3.44 0.53 0.32 -0.56 2.61 -0.40 1.35
Net Nonoperating Obligations (NNO)
107 153 151 46 -7.39 -10 -1.14 -66 -58 -77
Total Depreciation and Amortization (D&A)
3.21 3.16 4.90 4.43 4.54 4.47 4.64 4.72 4.50 4.34
Debt-free, Cash-free Net Working Capital to Revenue
12.78% 14.35% 14.99% 12.55% 11.38% 12.40% 14.51% 10.29% 10.77% 10.22%
Debt-free Net Working Capital to Revenue
13.86% 14.47% 15.00% 12.58% 12.02% 13.25% 14.81% 14.71% 15.19% 16.30%
Net Working Capital to Revenue
13.59% 14.21% 14.53% 11.93% 11.71% 12.91% 14.57% 14.45% 14.91% 15.97%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.94 $1.00 $0.82 $0.60 $0.37 $0.28 $0.08 ($0.47) $0.08 ($0.13)
Adjusted Weighted Average Basic Shares Outstanding
37.10M 37.01M 35.86M 35.35M 34.95M 35.16M 34.22M 33.96M 33.02M 33.38M
Adjusted Diluted Earnings per Share
$0.93 $0.99 $0.81 $0.60 $0.36 $0.28 $0.08 ($0.47) $0.08 ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding
37.49M 37.54M 36.56M 35.52M 35.15M 35.48M 34.60M 33.96M 33.06M 33.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
37.30M 36.82M 35.93M 35.80M 35.15M 34.73M 34.77M 33.81M 32.92M 32.81M
Normalized Net Operating Profit after Tax (NOPAT)
42 41 32 26 14 10.00 3.26 -12 2.90 2.27
Normalized NOPAT Margin
6.57% 6.50% 5.21% 4.77% 3.10% 2.41% 0.86% -3.50% 0.92% 0.73%
Pre Tax Income Margin
7.66% 6.90% 6.44% 5.61% 4.41% 3.13% 0.97% -5.76% 1.08% -1.26%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
14.92 9.09 11.87 7.22 30.14 23.00 8.98 -33.44 5.15 -6.99
NOPAT to Interest Expense
10.66 7.62 8.71 5.09 19.94 15.96 4.61 -23.67 3.91 -3.95
EBIT Less CapEx to Interest Expense
14.09 8.71 10.88 6.40 25.02 18.09 4.20 -38.46 3.11 -11.15
NOPAT Less CapEx to Interest Expense
9.82 7.24 7.71 4.27 14.82 11.06 -0.17 -28.69 1.87 -8.12
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
10.71% 18.97% 43.00% 57.71% 60.74% 79.38% 70.31% 500.28% -2,245.67% -256.32%

Frequently Asked Questions About Cross Country Healthcare's Financials

When does Cross Country Healthcare's fiscal year end?

According to the most recent income statement we have on file, Cross Country Healthcare's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cross Country Healthcare's net income changed over the last 2 years?

Cross Country Healthcare's net income appears to be on a downward trend, with a most recent value of -$14.56 million in 2024, falling from $185.98 million in 2022. The previous period was $72.63 million in 2023.

What is Cross Country Healthcare's operating income?
Cross Country Healthcare's total operating income in 2024 was -$16.87 million, based on the following breakdown:
  • Total Gross Profit: $1.32 billion
  • Total Operating Expenses: $1.34 billion
How has Cross Country Healthcare revenue changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's total revenue changed from $2.80 billion in 2022 to $1.34 billion in 2024, a change of -52.1%.

How much debt does Cross Country Healthcare have?

Cross Country Healthcare's total liabilities were at $170.29 million at the end of 2024, a 20.2% decrease from 2023, and a 65.8% decrease since 2022.

How much cash does Cross Country Healthcare have?

In the past 2 years, Cross Country Healthcare's cash and equivalents has ranged from $3.60 million in 2022 to $81.63 million in 2024, and is currently $81.63 million as of their latest financial filing in 2024.

How has Cross Country Healthcare's book value per share changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's book value per share changed from 12.11 in 2022 to 12.73 in 2024, a change of 5.1%.



This page (NASDAQ:CCRN) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners